When should the β-blocker window in cirrhosis close?
Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California.
Phillip S
PS
Ge
Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: barunyon@mednet.ucla.edu.
Bruce A
BA
Runyon
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D005260:Female; D006530:Hepatorenal Syndrome / Q000209:etiology*; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy*; D008103:Liver Cirrhosis / Q000188:drug therapy*; D008297:Male; D010538:Peritonitis / Q000150:complications*
D000319:Adrenergic beta-Antagonists